Gabather Overview

  • Founded
  • 2014

Founded
  • Status
  • Public

  • Employees
  • 4

Employees
  • Stock Symbol
  • GABA

Stock Symbol
  • Share Price
  • $0.35

  • (As of Friday Closing)

Gabather General Information

Description

Gabather AB is engaged in developing novel drugs to treat several diseases originating in the central nervous system. It has four main focus areas anti-psychotics, anti-depressants and anxiolytics, analgesics, as well as cognition-enhancing treatments, including for Alzheimer's disease.

Contact Information

Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Primary Industry
Drug Discovery
Other Industries
Pharmaceuticals
Stock Exchange
STO
Primary Office
  • Skeppsbron 2, 1 TR
  • 211 20 Malmo
  • Sweden
+46 070-777 00 00

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Gabather Stock Performance

(As of Friday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$0.35 $0.39 $0.33 - $0.76 $5.32M 13.6M 16.4K -$0.11

Gabather Financials Summary

In Thousands,
USD
TTM 30-Jun-2022 FY 2021 31-Dec-2021 FY 2020 31-Dec-2020 FY 2019 31-Dec-2019
EV 5,714 4,629 5,434 6,908
Revenue 0 0 0 0
EBITDA (1,455) (1,978) (1,622) (1,500)
Net Income (1,455) (1,979) (1,621) (1,510)
Total Assets 1,023 1,701 3,806 4,927
Total Debt 0 0 0 0
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Gabather Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Gabather‘s full profile, request access.

Request a free trial

Gabather Patents

Gabather Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
US-20210087193-A1 Triazoloquinazolinone synthesis Active 19-Dec-2017 0000000000
US-11434243-B2 Triazoloquinazolinone synthesis Active 19-Dec-2017 0000000000 0
EP-3752507-A1 Triazoloquinazolinone synthesis Pending 19-Dec-2017 0000000000
US-20110092525-A1 Gabaa receptor modulators Active 04-Apr-2008 0000000000
US-8809355-B2 Gabaa receptor modulators Active 04-Apr-2008 C07D487/04
To view Gabather’s complete patent history, request access »

Gabather Executive Team (4)

Name Title Board Seat Contact Info
Michael-Robin Witt Ph.D Acting Chief Executive Officer
Ola Skanung Chief Financial Officer
Mogens Nielsen CSO
You’re viewing 3 of 4 executive team members. Get the full list »

Gabather Board Members (5)

Name Representing Role Since
Gunilla Ekström Ph.D Self Board Member 000 0000
Karl Svensson Self Board Member 000 0000
Olov Sterner Gabather Board Member 000 0000
Svein Arild Mathisen Self Board Member 000 0000
You’re viewing 4 of 5 board members. Get the full list »

Gabather Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial